Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value

Summary of the Consolidated Text on Rare Diseases

On 26 May 2021, the Chamber of Deputies, after more than two years of work in the Social Affairs Committee, approved the bill ...
Read more "

Pharma Value Code of Ethics

Being aware of the right value of a drug is a conviction that has inspired Pharma Value's actions, ever since the choice of the ...
Read more "

Our meeting staff in Florence

Today from our LinkedIn page we are not telling you what is happening in the pharma world but what is happening at home ...
Read more "
SPECIAL DRUG EVALUATION COMMISSIONS. AIFA commissions from 2004 to 2021

SPECIAL DRUG EVALUATION COMMISSIONS. AIFA commissions from 2004 to 2021

NOMOS Centro Studi Parlamentari e Pharma Value hanno realizzato uno speciale sulle commissioni per la valutazione dei farmaci, precisamente la Commissione Tecnico ...
Read more "

Thoughts, the Newsletter

Pensierini sarà la Newsletter di Valeria Viola, una mail che non racconterà specificamente le attività di Pharma Value, così come non sarà ...
Read more "
Special - The rules for CTS and CPR renewal AIFA

The renewal of the AIFA Commissions is imminent. What are the rules?

A settembre scadranno le Commissioni AIFA (CTS e CPR). NOMOS centro studi parlamentari e Pharma Value fanno il punto sulle regole per ...
Read more "
Rare Diseases Table

Who are the members of the technical table for rare diseases of the Ministry of Health

Il 21 giugno 2021 è stato istituito il Tavolo tecnico in tema di malattie rare. Il Tavolo riunisce esperti clinici e accademici, ...
Read more "

Privilege is invisible to the eyes.

Abbiamo chiesto alla Fondazione Giacomo Brodolini di aiutarci a ragionare sul privilegio, in questo mese del Pride dove i social si colorano ...
Read more "
ERN and rare diseases - report

ERN and rare diseases: the report of the Incisive Health Morning Club co-organised by Nomos, in collaboration with Pharma Value

Il 20 maggio si è tenuto l’Incisive Health Morning Club co-organizzato da Nomos Centro Studi Parlamentari e Pharma Value in collaborazione con ...
Read more "
en_GB